DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: lubiprostone

Summary for Generic Name: lubiprostone

Tradenames:1
Patents:17
Applicants:1
NDAs:1
Drug Master File Entries: see list7
Suppliers: see list5
Therapeutic Class:Gastrointestinal Agents

Pharmacology for Ingredient: lubiprostone

Clinical Trials for: lubiprostone

Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation for Colonoscopy
Status: Completed Condition: Colorectal Carcinoma

Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)
Status: Completed Condition: Constipation-predominant Irritable Bowel Syndrome

Lubiprostone Effect on Gastrointestinal (GI) Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation
Status: Active, not recruiting Condition: Chronic Idiopathic Constipation

Amitiza® Plus GoLYTELY® Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation
Status: Completed Condition: Colonoscopy

Lubiprostone, Colonic Motility and Sensation
Status: Completed Condition: Healthy

Lubiprostone in Patients With Multiple Sclerosis Associated Constipation
Status: Recruiting Condition: Multiple Sclerosis; Constipation

Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
Status: Completed Condition: Adult; Irritable Bowel Syndrome; Constipation

The Effectiveness of Lubiprostone in Constipated Diabetics
Status: Recruiting Condition: Constipation; Diabetes

Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.
Status: Recruiting Condition: Chronic Constipation, Methanogenesis

Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications
Status: Completed Condition: Constipation

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908Jan 31, 2006RXYes<disabled>TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908Jan 31, 2006RXYes7,417,067<disabled>Y
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908Jan 31, 2006RXYes8,114,890<disabled>Y
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908Jan 31, 2006RXYes6,583,174<disabled>Y
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc